Pharma Marketletter - Boeh Ingelheim launches largest-ever stroke prevention trial with dipyridamole.
New scientific approaches for the prevention and acute treatment of stroke were the focus at the 12th European Stroke Conference in Valencia, Spain, last week. During the symposium and subsequent press conference, Germany’s Boehringer Ingelheim presented its comprehensive cerebrovascular protection program for acute and secondary stroke.
Most Popular
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
13 Job Interview Mistakes To Avoid
5 Regular Mistakes In Public Speaking
3 Questions No Job Seeker Ever Wants To Be Asked?
Experts discussed stroke prevention and treatment options with the platelet aggregation inhibitor Aggrenox/ Asasantin Retard (dipyridamole), the firm’s angiotensin-receptor blocker Micardis (telmisartan) and the tissue plasminogen activator Actilyse (alteplase); the latter has been co-developed by BI and Genentech.E …
Want to read the whole article? You can purchase it here. It’s quick and easy.
